FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 08/2023”.
The Monitor is a month-to-month revealed overview of enterprise capital traits within the US-Biotech sector.
As of the top of August 2023, we establish the next present VC traits within the US-Biotech sector:
- In 2023, total Biotech funding within the USA has reached USD 13,752m
- In comparison with August 2022 the financing quantity decreased by greater than 40% (23,189m vs. 13,752m)
- The highest 5 offers exceed USD 270m every, the most important transaction amounted to USD 401m with ElevateBio
- Cellares has the very best transaction Quantity of USD 255m in August, adopted by Genesis Therapeutics USD 224m and ADARx Prescription drugs USD 200m
- Flagship Pioneers (USA) is main the Prime 5 Traders (by deal quantity), adopted by ARCH Enterprise Companions (USA) and OrbiMed (USA)
- As a sign oncology information the very best funding exercise
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marcel-Louis Christou.